Free Trial
NASDAQ:GYRE

Gyre Therapeutics Q2 2026 Earnings Results & Report

Gyre Therapeutics logo
$4.74 +0.44 (+10.09%)
As of 01:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gyre Therapeutics missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 7, 2026. The company reported EPS of -$0.12 versus the -$0.0567 consensus estimate, while revenue of $29.11 million topped the $26.49 million estimate by $2.62 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Gyre Therapeutics EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.0567
Beat/Miss
Missed by -$0.0633
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Gyre Therapeutics Revenue Results

Actual Revenue
$29.11 million
Expected Revenue
$26.49 million
Beat/Miss
Beat by +$2.62 million
YoY Revenue Growth
N/A

Gyre Therapeutics Q2 2026 Earnings FAQ

Gyre Therapeutics (NASDAQ:GYRE) reported earnings of -$0.12 per share for Q2 2026, missing the consensus estimate of -$0.0567. The report was announced on Friday, August 7, 2026.

Gyre Therapeutics reported revenue of $29.11 million for Q2 2026, against a consensus estimate of $26.49 million.

Gyre Therapeutics Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Gyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email.

About Gyre Therapeutics

Gyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals.

Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

The company adopted the Gyre Therapeutics name in 2023, following its predecessor Catalyst Biosciences’ acquisition of a majority stake in Gyre Pharmaceuticals. This brought together U.S.-based drug development activities and established pharmaceutical operations in China.

View Gyre Therapeutics Profile